Cargando…

Preclinical and post-treatment changes in the HCC-associated serum proteome

SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ward, D G, Cheng, Y, N'Kontchou, G, Thar, T T, Barget, N, Wei, W, Martin, A, Beaugrand, M, Johnson, P J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360589/
https://www.ncbi.nlm.nih.gov/pubmed/17060939
http://dx.doi.org/10.1038/sj.bjc.6603429
_version_ 1782153086850039808
author Ward, D G
Cheng, Y
N'Kontchou, G
Thar, T T
Barget, N
Wei, W
Martin, A
Beaugrand, M
Johnson, P J
author_facet Ward, D G
Cheng, Y
N'Kontchou, G
Thar, T T
Barget, N
Wei, W
Martin, A
Beaugrand, M
Johnson, P J
author_sort Ward, D G
collection PubMed
description SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis C patients before development of HCC, with HCC and following radiofrequency ablation of the tumour. As with alpha-fetoprotein, an accepted biomarker for HCC, we hypothesised that HCC-associated proteomic features would ‘return to normal’ following successful treatment and the primary aim of our study was to test this hypothesis. Several SELDI peaks that changed significantly during HCC development were detected but they did not reverse following treatment. These data may be interpreted to suggest that the characteristic SELDI profile is not linearly related to tumour burden but may result from the progression of underlying liver disease or from the emergence of precancerous lesions. β2-Microglobulin, a protein previously reported to be markedly elevated in patients with HCV related HCC, was also the most significantly HCC associated proteomic feature (m/z 11720) in this study.
format Text
id pubmed-2360589
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23605892009-09-10 Preclinical and post-treatment changes in the HCC-associated serum proteome Ward, D G Cheng, Y N'Kontchou, G Thar, T T Barget, N Wei, W Martin, A Beaugrand, M Johnson, P J Br J Cancer Molecular Diagnostics SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis C patients before development of HCC, with HCC and following radiofrequency ablation of the tumour. As with alpha-fetoprotein, an accepted biomarker for HCC, we hypothesised that HCC-associated proteomic features would ‘return to normal’ following successful treatment and the primary aim of our study was to test this hypothesis. Several SELDI peaks that changed significantly during HCC development were detected but they did not reverse following treatment. These data may be interpreted to suggest that the characteristic SELDI profile is not linearly related to tumour burden but may result from the progression of underlying liver disease or from the emergence of precancerous lesions. β2-Microglobulin, a protein previously reported to be markedly elevated in patients with HCV related HCC, was also the most significantly HCC associated proteomic feature (m/z 11720) in this study. Nature Publishing Group 2006-11-20 2006-10-24 /pmc/articles/PMC2360589/ /pubmed/17060939 http://dx.doi.org/10.1038/sj.bjc.6603429 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular Diagnostics
Ward, D G
Cheng, Y
N'Kontchou, G
Thar, T T
Barget, N
Wei, W
Martin, A
Beaugrand, M
Johnson, P J
Preclinical and post-treatment changes in the HCC-associated serum proteome
title Preclinical and post-treatment changes in the HCC-associated serum proteome
title_full Preclinical and post-treatment changes in the HCC-associated serum proteome
title_fullStr Preclinical and post-treatment changes in the HCC-associated serum proteome
title_full_unstemmed Preclinical and post-treatment changes in the HCC-associated serum proteome
title_short Preclinical and post-treatment changes in the HCC-associated serum proteome
title_sort preclinical and post-treatment changes in the hcc-associated serum proteome
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360589/
https://www.ncbi.nlm.nih.gov/pubmed/17060939
http://dx.doi.org/10.1038/sj.bjc.6603429
work_keys_str_mv AT warddg preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT chengy preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT nkontchoug preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT thartt preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT bargetn preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT weiw preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT martina preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT beaugrandm preclinicalandposttreatmentchangesinthehccassociatedserumproteome
AT johnsonpj preclinicalandposttreatmentchangesinthehccassociatedserumproteome